The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

Two of the U.S. government’s most powerful banking regulators said, in response to pointed questions about their futures from ...

Netflix Inc. shares have been cruising this year, but Wall Street’s biggest bull says the party can keep roaring on.

Ford outlined plans to lay off 4,000 employees in the U.K. and Germany in response to a series of losses it blamed on ...

High equity valuations and investors’ concentration in big U.S. tech stocks are among the main risks to financial stability, ...

It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as ...

The second Trump administration could be a boon for stock pickers, according to a team of equity strategists at Barclays. In ...

Crude-oil futures edged higher on Wednesday following a “meaningful escalation” this week in tensions between Russia and ...

Earnings growth may drive up the S&P 500, even as investors worry the U.S. stock market is expensive after logging a series ...

Oil futures pared some of their gains on Wednesday after the Energy Information Administration reported that U.S. commercial ...

Analysts at Keefe, Bruyette & Woods downgraded shares of the Federal National Mortgage Association and Freddie Mac Wednesday to market perform from outperform, as the mortgage giants' stocks have ...

The New Jersey-based sub giant, reportedly valued at $8 billion, aims to grow beyond 3,000 locations in the U.S.